A Novel Neoplastic Fusion Transcript, RAD51AP1-DYRK4, Confers Sensitivity to the MEK Inhibitor Trametinib in Aggressive Breast Cancers
Abstract
Luminal B breast tumors are more aggressive estrogen receptor–positive (ER+) breast cancers characterized by aggressive clinical behavior and a high risk of metastatic dissemination. The underlying pathologic molecular events remain poorly understood with a paucity of actionable genetic drivers, which hinders the development of new treatment strategies.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Feb 01, 2021
- Source ID
- 10.1158/1078-0432.ccr-20-2769
Entities
People
- Chia-chia Liu
- Jamunarani Veeraraghavan
- Jin-ah Kim
- Sang Hyeon Lee
- Suet Kee Loo
- Xian Wang
- Xiao-song Wang
- Yiheng Hu
- Ying Tan
Organizations
- Baylor College of Medicine
- National Cancer Institute
- National Human Genome Research Institute
- National Institutes of Health
- Susan G. Komen for the Cure
- University of Pittsburgh